199 related articles for article (PubMed ID: 20497930)
1. Syndrome of inappropriate antidiuretic hormone associated with tolterodine therapy.
Bryan MK; Nguyen MT; Hilas O
Consult Pharm; 2010 May; 25(5):320-2. PubMed ID: 20497930
[TBL] [Abstract][Full Text] [Related]
2. Tolterodine.
Nurs Times; 2006 Jun 6-12; 102(23):27. PubMed ID: 16784047
[No Abstract] [Full Text] [Related]
3. Safety and tolerability of tolterodine for the treatment of overactive bladder in adults.
Roberts RG; Garely AD; Bavendam T
Am J Manag Care; 2005 Jul; 11(4 Suppl):S158-62. PubMed ID: 16161389
[TBL] [Abstract][Full Text] [Related]
4. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
[TBL] [Abstract][Full Text] [Related]
5. Hallucinations with tolterodine.
Williams SG; Staudenmeier J
Psychiatr Serv; 2004 Nov; 55(11):1318-9. PubMed ID: 15534031
[No Abstract] [Full Text] [Related]
6. Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70.
Jonas U; Rackley RR
Eur Urol; 2006 Jan; 49(1):187-8; author reply 188-90. PubMed ID: 16310930
[No Abstract] [Full Text] [Related]
7. [Overactive bladder. New anticholinergic drug controls urinary urge].
MMW Fortschr Med; 2004 Jul; 146(27-28):51. PubMed ID: 15526670
[No Abstract] [Full Text] [Related]
8. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
Abrams P; Kaplan S; De Koning Gans HJ; Millard R
J Urol; 2006 Mar; 175(3 Pt 1):999-1004; discussion 1004. PubMed ID: 16469601
[TBL] [Abstract][Full Text] [Related]
9. Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
Schaefer W
J Urol; 2006 Nov; 176(5):2311-2; author reply 2312-3. PubMed ID: 17070326
[No Abstract] [Full Text] [Related]
10. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability.
Kilic N; Balkan E; Akgoz S; Sen N; Dogruyol H
Int J Urol; 2006 Feb; 13(2):105-8. PubMed ID: 16563131
[TBL] [Abstract][Full Text] [Related]
11. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
12. [A drug seeks its disease].
Löfgren O
Lakartidningen; 2010 Jun 2-8; 107(22):1488-9. PubMed ID: 20645604
[No Abstract] [Full Text] [Related]
13. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
[TBL] [Abstract][Full Text] [Related]
14. Hyponatremia associated with tolterodine therapy.
Madewell KA; Kuo P
Am J Health Syst Pharm; 2008 Jun; 65(11):1054-6. PubMed ID: 18499879
[TBL] [Abstract][Full Text] [Related]
15. Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial.
Leung DY; Kwong YY; Lam DS
Br J Clin Pharmacol; 2005 Dec; 60(6):668; author reply 669. PubMed ID: 16305595
[No Abstract] [Full Text] [Related]
16. Effectiveness of tolterodine in nonneurogenic voiding dysfunction.
Babu R
Indian Pediatr; 2006 Nov; 43(11):980-3. PubMed ID: 17151401
[TBL] [Abstract][Full Text] [Related]
17. Tolterodine-associated acute mixed liver injury.
Schlienger RG; Keller MJ; Krähenbühl S
Ann Pharmacother; 2002 May; 36(5):817-9. PubMed ID: 11978158
[TBL] [Abstract][Full Text] [Related]
18. Transient memory impairment and hallucinations associated with tolterodine use.
Tsao JW; Heilman KM
N Engl J Med; 2003 Dec; 349(23):2274-5. PubMed ID: 14657444
[No Abstract] [Full Text] [Related]
19. Risk of serious falls associated with oxybutynin and tolterodine: a population based study.
Gomes T; Juurlink DN; Ho JM; Schneeweiss S; Mamdani MM
J Urol; 2011 Oct; 186(4):1340-4. PubMed ID: 21855905
[TBL] [Abstract][Full Text] [Related]
20. [A meta-analysis documenting the optimal tolerance profile of tolterodine].
Rev Med Suisse; 2006 May; 2(65):1234. PubMed ID: 16767876
[No Abstract] [Full Text] [Related]
[Next] [New Search]
